Rigel Pharmaceuticals (RIGL) Accounts Payables (2010 - 2026)

Rigel Pharmaceuticals' Accounts Payables history runs 17 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 13.45% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $4.5 million (up 13.45% YoY), while the FY2025 annual figure was $7.2 million, up 115.36% from the prior year.
• Accounts Payables was $4.5 million for Q1 2026 at Rigel Pharmaceuticals, down from $7.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $15.0 million in Q4 2022 to a low of $2.2 million in Q2 2022.
• Historically, Accounts Payables has averaged $5.9 million across 5 years, with a median of $5.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables jumped 295.26% in 2022, then plunged 57.37% in 2025.
• A 5-year view of Accounts Payables shows it stood at $15.0 million in 2022, then tumbled by 52.39% to $7.1 million in 2023, then tumbled by 53.25% to $3.3 million in 2024, then soared by 115.36% to $7.2 million in 2025, then slumped by 37.62% to $4.5 million in 2026.
• The last three Accounts Payables figures came in at $4.5 million (Q1 2026), $7.2 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.